# Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct03519230/  
OnCo record `nct03519230` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pamiparib capsule in ovarian cancer, run by BeiGene, active and no longer recruiting.

## Summary

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT03519230 by BeiGene, with 224 participants enrolled, started 2018-05-14 and due to reach its primary completion in 2025-12-01. Interventions recorded: Pamiparib capsule and Placebo capsule.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03519230
- Phase: 3
- Setting: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Sponsor: BeiGene
- Enrolled: 224

## Sources

- ClinicalTrials.gov NCT03519230: https://clinicaltrials.gov/study/NCT03519230

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)
- drugs: [Pamiparib](https://onco.cc/drugs/pamiparib/)

---
JSON: https://onco.cc/api/v1/entities/nct03519230.json